Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 13/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CD74 | P04233 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737457 | 0.88 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737143 | 0.87 | HDAC3 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737323 | 0.87 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737124 | 0.84 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737117 | 0.83 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737360 | 0.82 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737131 | 0.82 | HDAC3 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737373 | 0.76 | KDM6B (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737284 | 0.75 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30737278 | 0.74 | HDAC3 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | HDAC3 2244/4885HDAC4 2559/4885HDAC1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.